DE19926154A1 - Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung - Google Patents

Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung

Info

Publication number
DE19926154A1
DE19926154A1 DE19926154A DE19926154A DE19926154A1 DE 19926154 A1 DE19926154 A1 DE 19926154A1 DE 19926154 A DE19926154 A DE 19926154A DE 19926154 A DE19926154 A DE 19926154A DE 19926154 A1 DE19926154 A1 DE 19926154A1
Authority
DE
Germany
Prior art keywords
active ingredient
spacer
protein
group
active substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE19926154A
Other languages
German (de)
English (en)
Inventor
Felix Kratz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vergell Medical Sa Ch
Original Assignee
KTB Tumorforschungs GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7910588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE19926154(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by KTB Tumorforschungs GmbH filed Critical KTB Tumorforschungs GmbH
Priority to DE19926154A priority Critical patent/DE19926154A1/de
Priority to DE50013468T priority patent/DE50013468D1/de
Priority to AU59709/00A priority patent/AU779697B2/en
Priority to ES00945721T priority patent/ES2269160T3/es
Priority to EP00945721A priority patent/EP1183050B1/de
Priority to AT00945721T priority patent/ATE339225T1/de
Priority to PT00945721T priority patent/PT1183050E/pt
Priority to US09/980,266 priority patent/US7387771B1/en
Priority to EP10183870.4A priority patent/EP2347770B2/de
Priority to ES06012171T priority patent/ES2385230T3/es
Priority to JP2001502882A priority patent/JP5517384B2/ja
Priority to ES10183870T priority patent/ES2623017T5/es
Priority to PT101838704T priority patent/PT2347770T/pt
Priority to EP06012171A priority patent/EP1704864B9/de
Priority to PT06012171T priority patent/PT1704864E/pt
Priority to PCT/EP2000/005272 priority patent/WO2000076551A2/de
Priority to DK10183870.4T priority patent/DK2347770T4/da
Priority to DK06012171.2T priority patent/DK1704864T3/da
Priority to CA2374964A priority patent/CA2374964C/en
Priority to DK00945721T priority patent/DK1183050T3/da
Priority to SI200031070T priority patent/SI1704864T1/sl
Publication of DE19926154A1 publication Critical patent/DE19926154A1/de
Priority to US11/388,733 priority patent/US20060233707A1/en
Priority to CY20061101464T priority patent/CY1105701T1/el
Priority to US12/604,093 priority patent/US8153581B2/en
Priority to JP2011102053A priority patent/JP5871483B2/ja
Priority to US13/414,316 priority patent/US8846602B2/en
Priority to CY20121100751T priority patent/CY1113370T1/el
Priority to JP2013268998A priority patent/JP2014055192A/ja
Priority to US14/469,232 priority patent/US20150196573A1/en
Priority to JP2015252087A priority patent/JP6290166B2/ja
Priority to JP2017214959A priority patent/JP6573947B2/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE19926154A 1999-06-09 1999-06-09 Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung Ceased DE19926154A1 (de)

Priority Applications (31)

Application Number Priority Date Filing Date Title
DE19926154A DE19926154A1 (de) 1999-06-09 1999-06-09 Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
SI200031070T SI1704864T1 (sl) 1999-06-09 2000-06-07 Injekcijski pripravek zdravila, ki sestoji iz citostatika in maleinimidne skupine, vezane z vmestnikom
PT06012171T PT1704864E (pt) 1999-06-09 2000-06-07 Preparação farmacêutica injectável que consiste num agente citostático e num grupo maleinimida ligados por um espaçador
DK10183870.4T DK2347770T4 (da) 1999-06-09 2000-06-07 Fremgangsmåde til fremstilling af en injicerbar farmaceutisk tilberedning
ES00945721T ES2269160T3 (es) 1999-06-09 2000-06-07 Procedimiento para la preparacion de una formulacion medicamentosa inyectable.
EP00945721A EP1183050B1 (de) 1999-06-09 2000-06-07 Verfahren zur herstellung einer injizierbaren arzneimittelzubereitung
AT00945721T ATE339225T1 (de) 1999-06-09 2000-06-07 Verfahren zur herstellung einer injizierbaren arzneimittelzubereitung
PT00945721T PT1183050E (pt) 1999-06-09 2000-06-07 Processo para a produção de uma preparação farmacêutica injectável
DK06012171.2T DK1704864T3 (da) 1999-06-09 2000-06-07 Injicerbar farmaceutisk tilberedning bestående af et cytostatisk middel og et maleinimid forbundet med en spacer
EP10183870.4A EP2347770B2 (de) 1999-06-09 2000-06-07 Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
ES06012171T ES2385230T3 (es) 1999-06-09 2000-06-07 Formulación farmacéutica inyectable que consiste en un agente citostático y una maleimida que se unen por medio de un espaciador
AU59709/00A AU779697B2 (en) 1999-06-09 2000-06-07 Method for producing an injectable medicament preparation
ES10183870T ES2623017T5 (es) 1999-06-09 2000-06-07 Procedimiento para la preparación de una formulación medicamentosa inyectable
PT101838704T PT2347770T (pt) 1999-06-09 2000-06-07 Processo de produção de uma preparação farmacêutica injetável
EP06012171A EP1704864B9 (de) 1999-06-09 2000-06-07 Injizierbare Arzneimittelzubereitung bestehend aus einem Zytostatikum und einer durch einen Spacer gebundenen Maleinimidgruppe.
DE50013468T DE50013468D1 (de) 1999-06-09 2000-06-07 Verfahren zur herstellung einer injizierbaren arzneimittelzubereitung
PCT/EP2000/005272 WO2000076551A2 (de) 1999-06-09 2000-06-07 Verfahren zur herstellung einer injizierbaren arzneimittelzubereitung
JP2001502882A JP5517384B2 (ja) 1999-06-09 2000-06-07 注射可能な医薬調製剤の製法
US09/980,266 US7387771B1 (en) 1999-06-09 2000-06-07 Method for producing an injectable medicament preparation
CA2374964A CA2374964C (en) 1999-06-09 2000-06-07 Process for producing an injectable medicament preparation
DK00945721T DK1183050T3 (da) 1999-06-09 2000-06-07 Fremgangsmåde til fremstilling af et injicerbart lægemiddelpræparat
US11/388,733 US20060233707A1 (en) 1999-06-09 2006-03-24 Process for producing an injectable medicament preparation
CY20061101464T CY1105701T1 (el) 1999-06-09 2006-10-12 Μεθοδος δια την παρασκευη ενος ενεσιμου φαρμακευτικου σκευασματος
US12/604,093 US8153581B2 (en) 1999-06-09 2009-10-22 Process for producing an injectable medicament preparation
JP2011102053A JP5871483B2 (ja) 1999-06-09 2011-04-28 注射可能な医薬調製剤の製法
US13/414,316 US8846602B2 (en) 1999-06-09 2012-03-07 Process for producing an injectable medicament preparation
CY20121100751T CY1113370T1 (el) 1999-06-09 2012-08-22 Ενεσιμο φαρμακευτικο σκευασμα αποτελουμενο απο ενα κυτταροστατικο και μια μηλεϊνιμιδο ομαδα συνδεομενη δια ενος παρεμβαλλομενου μοριου
JP2013268998A JP2014055192A (ja) 1999-06-09 2013-12-26 注射可能な医薬調製剤の製法
US14/469,232 US20150196573A1 (en) 1999-06-09 2014-08-26 Process for producing an injectable medicament preparation
JP2015252087A JP6290166B2 (ja) 1999-06-09 2015-12-24 注射可能な医薬調製剤の製法
JP2017214959A JP6573947B2 (ja) 1999-06-09 2017-11-07 注射可能な医薬調製剤の製法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19926154A DE19926154A1 (de) 1999-06-09 1999-06-09 Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung

Publications (1)

Publication Number Publication Date
DE19926154A1 true DE19926154A1 (de) 2000-12-14

Family

ID=7910588

Family Applications (2)

Application Number Title Priority Date Filing Date
DE19926154A Ceased DE19926154A1 (de) 1999-06-09 1999-06-09 Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
DE50013468T Expired - Lifetime DE50013468D1 (de) 1999-06-09 2000-06-07 Verfahren zur herstellung einer injizierbaren arzneimittelzubereitung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE50013468T Expired - Lifetime DE50013468D1 (de) 1999-06-09 2000-06-07 Verfahren zur herstellung einer injizierbaren arzneimittelzubereitung

Country Status (13)

Country Link
US (5) US7387771B1 (es)
EP (3) EP2347770B2 (es)
JP (5) JP5517384B2 (es)
AT (1) ATE339225T1 (es)
AU (1) AU779697B2 (es)
CA (1) CA2374964C (es)
CY (2) CY1105701T1 (es)
DE (2) DE19926154A1 (es)
DK (3) DK2347770T4 (es)
ES (3) ES2385230T3 (es)
PT (3) PT1704864E (es)
SI (1) SI1704864T1 (es)
WO (1) WO2000076551A2 (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078781A1 (de) * 2003-03-07 2004-09-16 Ktb Tumorforschungs Gmbh Protein-bindende doxorubicin-peptid-derivate
DE102006024528A1 (de) * 2006-05-23 2007-11-29 Albupharm Heidelberg Gmbh & Co. Kg Neue, an der Tumorphysiologie orientierte Formulierung eines Zytostatikums, insbesondere von cis-Platin

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7144854B1 (en) 1999-09-10 2006-12-05 Conjuchem, Inc. Long lasting anti-angiogenic peptides
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
ES2209885T3 (es) 1999-05-17 2004-07-01 Conjuchem, Inc. Peptidos insulinotropicos de larga duracion.
EP1264840B1 (en) 1999-05-17 2009-09-23 ConjuChem Biotechnologies Inc. Long lasting fusion peptide inhibitors of viral infection
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
DE19926475A1 (de) * 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
EP1889639A3 (en) * 1999-09-07 2008-04-09 ConjuChem Biotechnologies Inc. Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents, for producing long lasting antineoplastic agents
US6706892B1 (en) 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
EP1235618A2 (en) * 1999-09-07 2002-09-04 Conjuchem, Inc. Bioconjugation in vivo to pulmonary or blood components
US7090851B1 (en) 1999-09-10 2006-08-15 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
US6961567B1 (en) * 2000-12-07 2005-11-01 Palm, Inc. Generic activation and registration framework for wireless devices
US7555571B1 (en) * 2001-01-05 2009-06-30 Palm, Inc. Activation of mobile computing device on a cellular network
CA2435563A1 (en) 2001-02-02 2002-08-15 Conjuchem Inc. Long lasting growth hormone releasing factor derivatives
EP1360202B1 (en) 2001-02-16 2008-05-21 ConjuChem Biotechnologies Inc. Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
US8812398B2 (en) * 2001-05-08 2014-08-19 Qualcomm Incorporated Key for a wireless-enabled device
WO2002096935A2 (en) 2001-05-31 2002-12-05 Conjuchem, Inc. Long lasting fusion peptide inhibitors for hiv infection
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US8435529B2 (en) 2002-06-14 2013-05-07 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
JP4959136B2 (ja) 2002-12-13 2012-06-20 イミューノメディクス、インコーポレイテッド 細胞内で開裂可能な結合を有する免疫接合体
GB0321613D0 (en) * 2003-09-15 2003-10-15 Drug Discovery Lab As Compounds
EP2100904B1 (en) * 2004-04-23 2010-07-07 ConjuChem Biotechnologies Inc. Solid phase for use in a method for the purification of albumin conjugates
DE102005002991A1 (de) * 2005-01-21 2006-07-27 Rösner Research GmbH & Co.KG Verfahren zur Herstellung von Albumin-Konjugaten mit Gyrasehemmern
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US8039432B2 (en) * 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
DE102007002726A1 (de) * 2007-01-18 2008-07-31 Bayer Schering Pharma Aktiengesellschaft Neue Kaskaden-Polymer-Komplexe, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel
JP2010518135A (ja) * 2007-02-16 2010-05-27 ケイテーベー ツモルフォルシュングスゲゼルシャフト ミット ベシュレンクテル ハフツング 二重作用プロドラッグ
LT3912643T (lt) 2009-02-13 2023-02-10 Immunomedics Inc. Imunokonjugatai su ląstelės viduje skaldoma jungtimi
EP2289558A1 (en) * 2009-08-25 2011-03-02 KTB Tumorforschungsgesellschaft mbH Bisphosphonate-prodrugs
EP2359802B1 (en) * 2010-02-12 2014-06-18 Evonik Degussa GmbH Cosmetic composition containing polyglycerol partial ester
EP2382993A1 (en) * 2010-04-19 2011-11-02 KTB Tumorforschungsgesellschaft mbH Combination of drugs with protein-binding prodrugs
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
EP3915369A1 (en) 2012-12-13 2021-12-01 CytRx Corporation Anthracycline formulations
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
WO2015012904A2 (en) 2012-12-13 2015-01-29 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
SI2900277T1 (sl) 2012-12-13 2022-05-31 Immunomedics, Inc. Odmerki imunokonjugatov protiteles in SN-38 za boljšo učinkovitost in zmanjšano toksičnost
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
MY169117A (en) 2012-12-21 2019-02-18 Bioalliance Cv Hydrophilic self-immolative linkers and conjugates thereof
NZ631022A (en) * 2013-06-05 2018-05-25 Cytrx Corp Cytotoxic agents for the treatment of cancer
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
WO2015196167A1 (en) 2014-06-20 2015-12-23 Bioalliance C.V. Anti-folate receptor aplha (fra) antibody-drug conjugates and methods of using thereof
US9775914B2 (en) 2014-11-20 2017-10-03 Pharosgen Co., Ltd. Prodrugs activated by caspase
CN107428837A (zh) 2015-04-22 2017-12-01 免疫医疗公司 循环trop‑2阳性癌细胞的分离、检测、诊断和/或鉴定
WO2016205738A2 (en) 2015-06-19 2016-12-22 Cytrx Corporation Delivery systems for controlled drug release
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
ES2898704T3 (es) 2015-12-09 2022-03-08 Univ Wien Med Compuestos de platino funcionalizados con monomaleimida para la terapia del cáncer
TWI753875B (zh) 2016-01-08 2022-02-01 美商美國全心醫藥生技股份有限公司 四價抗psgl-1抗體及其用途
WO2017139623A1 (en) 2016-02-10 2017-08-17 Immunomedics, Inc. Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
WO2017147240A1 (en) 2016-02-23 2017-08-31 Tarveda Therapeutics, Inc. Hsp90 targeted conjugates and particles and formulations thereof
JP7379795B2 (ja) 2016-04-27 2023-11-15 イミューノメディクス、インコーポレイテッド チェックポイント阻害薬に再発／耐性を示す腫瘍を治療するための抗Ｔｒｏｐ－２－ＳＮ－３８抗体薬物複合体の効果
US10918734B2 (en) 2017-03-27 2021-02-16 Immunomedics, Inc. Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51
WO2018187074A1 (en) 2017-04-03 2018-10-11 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
KR20230115351A (ko) 2017-08-15 2023-08-02 난트셀, 인크. Hank 세툭시맙 조합 및 방법
JP2021014409A (ja) * 2017-11-21 2021-02-12 京都薬品工業株式会社 タンパク質結合性薬物
KR20200117988A (ko) 2017-11-30 2020-10-14 센추리온 바이오파마 코포레이션 메이탄시노이드계 약물 전달 시스템
JP7359449B2 (ja) 2017-11-30 2023-10-11 センチュリオン バイオファーマ コーポレイション オーリスタチンｅ誘導体のアルブミン結合プロドラッグ

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003412A1 (en) * 1986-11-14 1988-05-19 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4251445A (en) 1978-03-24 1981-02-17 Weltman Joel K N-succinimidyl haloacetyl aminobenzoates as coupling agents
EP0024464B1 (en) 1979-08-29 1982-05-12 Nihon Medi-Physics Co., Ltd. 2-oxopropionaldehyde bis(thiosemicarbazone)derivatives and their production and use
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
EP0493745A1 (en) 1990-12-21 1992-07-08 Dojindo Laboratories Fluorescent compound, complex, reagent, and specific binding assay employing said reagent
DE4122210C2 (de) 1991-07-04 1999-04-01 Deutsches Krebsforsch Konjugate aus tumoraktiver Verbindung und Serumalbumin sowie Verfahren zu deren Herstellung und ihre Verwendung
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
BR9508951A (pt) 1994-09-13 1999-04-06 Theratech Inc Liberação intracelular de agentes químicos para um tipo específico de célula
IT1282625B1 (it) * 1996-02-14 1998-03-31 Zambon Spa Composizione farmaceutica atta ad inibire la formazione di metastasi tumorali
US5840733A (en) * 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
DE19636889A1 (de) 1996-09-11 1998-03-12 Felix Dr Kratz Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
US5879897A (en) 1996-09-23 1999-03-09 Wake Forest University Methods and compositions for the diagnosis of extraesophageal gastric reflux
WO1998036777A1 (en) * 1997-02-20 1998-08-27 Dime David S Site-specific drug delivery
EP2341058A3 (en) 1997-09-12 2011-11-23 Exiqon A/S Oligonucleotide Analogues
IL133053A0 (en) * 1998-03-23 2001-03-19 Conjuchem Inc Local delivery of long lasting therapeutic agents
DE19923168A1 (de) 1999-05-20 2000-11-23 Roche Diagnostics Gmbh Neue Fluoreszenzfarbstoffe und ihre Verwendung als Fluoreszenzmarker
DE19926154A1 (de) * 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
DE19926475A1 (de) * 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
US20060233701A1 (en) 2005-03-30 2006-10-19 Thomas Parias Method and apparatus to improve the industrial production of hydrogen-carbon monoxide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003412A1 (en) * 1986-11-14 1988-05-19 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078781A1 (de) * 2003-03-07 2004-09-16 Ktb Tumorforschungs Gmbh Protein-bindende doxorubicin-peptid-derivate
US7803903B2 (en) 2003-03-07 2010-09-28 Ktb Tumorforschungs Gmbh Protein-binding doxorubicin peptide derivatives
DE102006024528A1 (de) * 2006-05-23 2007-11-29 Albupharm Heidelberg Gmbh & Co. Kg Neue, an der Tumorphysiologie orientierte Formulierung eines Zytostatikums, insbesondere von cis-Platin

Also Published As

Publication number Publication date
EP2347770B2 (de) 2019-10-23
DK2347770T3 (en) 2017-07-03
ATE339225T1 (de) 2006-10-15
US20060233707A1 (en) 2006-10-19
WO2000076551A3 (de) 2001-08-16
SI1704864T1 (sl) 2012-09-28
EP1704864B1 (de) 2012-05-23
AU5970900A (en) 2001-01-02
JP2014055192A (ja) 2014-03-27
EP1704864A2 (de) 2006-09-27
DK1704864T3 (da) 2012-09-03
EP1704864A3 (de) 2007-01-10
EP2347770B1 (de) 2017-03-08
WO2000076551A2 (de) 2000-12-21
DK1183050T3 (da) 2007-01-02
CY1113370T1 (el) 2016-06-22
US8153581B2 (en) 2012-04-10
EP2347770A3 (de) 2011-11-09
CA2374964C (en) 2012-05-22
JP2018035191A (ja) 2018-03-08
ES2269160T3 (es) 2007-04-01
AU779697B2 (en) 2005-02-10
EP1183050B1 (de) 2006-09-13
PT2347770T (pt) 2017-06-20
JP2011173913A (ja) 2011-09-08
ES2623017T3 (es) 2017-07-10
US20100215574A1 (en) 2010-08-26
CY1105701T1 (el) 2010-12-22
DK2347770T4 (da) 2020-02-03
US7387771B1 (en) 2008-06-17
EP1704864B9 (de) 2012-09-19
JP5871483B2 (ja) 2016-03-01
US8846602B2 (en) 2014-09-30
ES2385230T3 (es) 2012-07-19
JP2003501486A (ja) 2003-01-14
ES2623017T5 (es) 2020-04-07
JP2016047847A (ja) 2016-04-07
DE50013468D1 (de) 2006-10-26
JP6573947B2 (ja) 2019-09-11
US20120195832A1 (en) 2012-08-02
PT1183050E (pt) 2007-01-31
PT1704864E (pt) 2012-07-02
CA2374964A1 (en) 2000-12-21
EP1183050A2 (de) 2002-03-06
EP2347770A2 (de) 2011-07-27
JP6290166B2 (ja) 2018-03-07
US20150196573A1 (en) 2015-07-16
JP5517384B2 (ja) 2014-06-11

Similar Documents

Publication Publication Date Title
EP1183050B1 (de) Verfahren zur herstellung einer injizierbaren arzneimittelzubereitung
EP1198254B1 (de) Träger-pharmaka-konjugate
DE10012120A1 (de) Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel
EP1601686B1 (de) Protein-bindende doxorubicin-peptid-derivate
DE102005009084A1 (de) Proteinbindende Anthrazyklin-Peptid-Derivate und diese enthaltende Arzneimittel
EP2046813B1 (de) Proteinbindende methotrexat-derivate und diese enthaltende arzneimittel

Legal Events

Date Code Title Description
OM8 Search report available as to paragraph 43 lit. 1 sentence 1 patent law
8141 Disposal/no request for examination
8110 Request for examination paragraph 44
8170 Reinstatement of the former position
R016 Response to examination communication
R079 Amendment of ipc main class

Free format text: PREVIOUS MAIN CLASS: A61K0047480000

Ipc: A61K0047500000

R081 Change of applicant/patentee

Owner name: VERGELL MEDICAL S.A., CH

Free format text: FORMER OWNER: KTB TUMORFORSCHUNGSGESELLSCHAFT MBH, 79106 FREIBURG, DE

R082 Change of representative

Representative=s name: WEICKMANN & WEICKMANN PATENTANWAELTE - RECHTSA, DE

Representative=s name: WEICKMANN & WEICKMANN PATENT- UND RECHTSANWAEL, DE

R071 Expiry of right
R409 Internal rectification of the legal status completed
R002 Refusal decision in examination/registration proceedings
R003 Refusal decision now final